The pathway hyperactivation occurs mainly due to oncogenic mutations in PIK3CA gene encoding the p110a catalytic subunit of the PI3Kα heterodimeric protein complex, observed in approximately 40% of HR + /HER2- BC patients [2]. Here, ERBB2 is linked to breast cancer.